GlaxoSmithKline Consumer Healthcare registered a 9 per cent increase in its net profit to ₹160 crore for the quarter ended September 30, against ₹146.93 crore in the corresponding quarter of the last fiscal.
Net sales grew 11 per cent to ₹1,075 crore from the same period last fiscal.
Zubair Ahmed, Managing Director, GlaxoSmithKline Consumer Healthcare Ltd, said, “We are delighted to have delivered consistent growth as the category leader.”
“The consumer sentiment is showing early signs of recovery and our brands are well poised to help consumers do more, feel better and live longer. Our relentless focus on science, innovation and customer, remains our key differentiator and helps us to stay ahead in the category.” He added, “We continue to improve consumer’s experience with new products like the re-launched Horlicks with proven health benefits, and new positioning, highlighting its daily nutritional relevance. We also remain focused on our access strategy to ensure that our products are within the easy reach of our large consumer base.”
On Wednesday, the company’s stock closed at ₹5407.65, down 2.39 per cent, on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.